Acrivon Therapeutics, Inc. Quarterly Depreciation in USD from Q3 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q3 2021 to Q3 2024.
  • Acrivon Therapeutics, Inc. Depreciation for the quarter ending September 30, 2024 was $300K, a 200% increase year-over-year.
  • Acrivon Therapeutics, Inc. Depreciation for the twelve months ending September 30, 2024 was $935K, a 111% increase year-over-year.
  • Acrivon Therapeutics, Inc. annual Depreciation for 2023 was $536K, a 47.3% increase from 2022.
  • Acrivon Therapeutics, Inc. annual Depreciation for 2022 was $364K, a 884% increase from 2021.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $935K $300K +$200K +200% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $735K $200K +$100K +100% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $635K $224K +$99K +79.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $536K $211K +$92K +77.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $444K $100K $0 0% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $444K $100K $0 0% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $444K $125K +$80K +178% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $364K $119K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $100K +$91K +1011% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $100K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $45K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 $9K Jul 1, 2021 Sep 30, 2021 10-Q 2022-12-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.